TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from HC Wainwright

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright also issued estimates for TScan Therapeutics’ FY2029 earnings at $0.44 EPS.

Other analysts have also recently issued research reports about the stock. Needham & Company LLC cut their price target on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a report on Wednesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.20.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.98 on Thursday. The stock has a market cap of $105.67 million, a P/E ratio of -1.87 and a beta of 0.91. The firm’s fifty day simple moving average is $2.43 and its 200 day simple moving average is $4.04. TScan Therapeutics has a twelve month low of $1.82 and a twelve month high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, research analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Trading of TScan Therapeutics

A number of hedge funds have recently modified their holdings of TCRX. Checkpoint Capital L.P. bought a new stake in shares of TScan Therapeutics during the 3rd quarter valued at $4,110,000. abrdn plc boosted its holdings in shares of TScan Therapeutics by 137.8% during the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after buying an additional 512,049 shares in the last quarter. State Street Corp boosted its holdings in shares of TScan Therapeutics by 24.4% during the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after buying an additional 148,414 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock worth $851,000 after purchasing an additional 145,731 shares in the last quarter. Finally, Lynx1 Capital Management LP boosted its stake in TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock worth $16,286,000 after purchasing an additional 132,747 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.